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Review Article
Role of Radical Prostatectomy for High-Risk Prostate Cancer
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Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
High-risk localized prostate cancer traditionally includes patients with clinical T3 di-
sease but also includes those with apparently localized disease but with adverse prog-
nostic factors such as a Gleason score of 8 to 10, prostate-specific antigen of more than 
20 ng/ml, or extensive disease on biopsy. In the past, these patients were treated primar-
ily with radiation therapy due to concerns that surgery was not likely to be curative 
and was associated with a high incidence of side-effects. In addition, the lack of random-
ized trials comparing curative treatments for high-risk prostate cancer makes treat-
ment decisions in this patient population difficult. Several retrospective series have 
reported the long-term efficacy of radical prostatectomy monotherapy in a high-risk 
population, showing that the 5-year cancer-specific survival rate was more than 80% 
and the 5-year biochemical recurrence-free survival rate was about 50%. In addition, 
comparisons of different treatment options by means of nonrandomized trials have 
shown improved outcomes with surgery compared with radiation therapy or obser-
vation. Thus, there is renewed interest in radical prostatectomy as the primary treat-
ment for patients with high-risk prostate cancer. Here, we reviewed the outcomes of 
radical prostatectomy, with or without neoadjuvant or adjuvant therapies, in high-risk 
patients and what is known about the choice and timing of adjuvant therapies.
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INTRODUCTION
The wide application of prostate-specific antigen (PSA) 
screening has led not only to a higher incidence of prostate 
cancer, but also to a profound stage migration [1]. With this 
remarkable stage migration, 91% of cases are being detected 
as clinically localized prostate cancer, whereas the pro-
portion of metastatic disease at the time of diagnosis was 
just 4% in the United States in 2009 [2]. Because the natural 
history of clinically localized prostate cancer varies from 
indolent disease to highly aggressive disease, the risk strat-
ification of disease poses a significant challenge to the 
physician who treats patients with clinically localized pros-
tate cancer. The potential aggressiveness of each tumor 
and the general health, life expectancy, and quality of life 
preferences of each patient must be assessed prior to selecting 
treatment. Although the optimal treatment for clinically 
localized prostate cancer has not been established because 
of a lack of randomized controlled trials, both radical pros-
tatectomy (RP) and radiation therapy (RT) have excellent 
outcomes for low- and intermediate-risk disease. However, 
there is no consensus on the optimal treatment for high-risk 
localized prostate cancer, and much debate exists regard-
ing the ideal treatment approach [3]. Most urologists rec-
ommend androgen-deprivation therapy (ADT) plus ex-
ternal- beam radiation therapy (EBRT), with only about 
36% of high-risk patients initially treated with RP [4]. 
　The aim of this article is to enable physicians to identify 
patients with high-risk localized prostate cancer and to re-
view current data on the role of RP monotherapy for these 
patients. We have also reviewed current data about mul-
ti-modality therapies for patients with high-risk prostate 
cancer, including RP combined with neoadjuvant or ad-
juvant ADT and/or RT.
DEFINITION OF HIGH-RISK PROSTATE CANCER
Pretreatment risk stratification of newly diagnosed, clin-Korean J Urol 2010;51:589-595
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FIG. 1. Progression-free probability for patients with high-risk 
prostate cancer treated with radical prostatectomy alone by 
various definitions. Adapted with permission [16]. GS: Gleason
score, PSA: prostate-specific antigen, PFP: progression-free
probability.
ically localized prostate cancer to predict the likelihood of 
treatment failure is essential for counseling and informed 
decision making. The risk of relapse following therapy has 
been estimated by using multiple definitions ranging from 
a single parameter, including clinical stage [5], biopsy 
Gleason score (GS) [6], and PSA [7], to a combination of vari-
ables [8] to scoring systems [9] or nomogram definition [10].
　To date, however, there is no universally accepted defi-
nition of high-risk prostate cancer, and not all clinically 
high-risk prostate cancers defined by a single parameter 
are pathologically high-risk prostate cancers with a high 
likelihood of progression. Clinical staging by digital rectal 
examination failed to detect extraprostatic extension in 
24% of patients [11] and over-staged organ-confined dis-
ease in 27% [5]. Poorly differentiated prostate cancer on bi-
opsy is often downgraded in the final RP specimen [12]. 
Although high PSA concentration may be indicative of tu-
mor burden, it may also be high due to benign prostatic hy-
perplasia or inflammation [13].
　The most commonly accepted definition was proposed by 
D’Amico et al and defines high-risk prostate cancer as PSA 
more than 20 ng/ml or GS of 8 to 10 or clinical stage of at 
least T2c [8]. The proportion of patients presenting with 
high-risk prostate cancer by this definition decreased from 
40.9% in 1989 to 1990 to 14.8% in 2001 to 2002. The down-
ward stage migration due to widespread PSA screening re-
sulted in a significant shift in the determinants of prostate 
cancer risk stratification, with GS now more likely and PSA 
less likely to drive risk assignment [14]. The high-risk defi-
nition proposed by D’Amico et al is also used in the European 
Association of Urology (EAU) guidelines on prostate cancer 
[3]. The 2010 National Comprehensive Cancer Network 
(NCCN) guidelines define patients with clinically localized, 
high-risk disease as those with clinical stage T3a disease, 
GS 8 to 10, or PSA more than 20 ng/ml and very- high-risk 
patients as those with clinical stage T3b-T4 disease [15].
　The definition of high-risk prostate cancer influences the 
prediction of extraprostatic disease and treatment outcome. 
For example, a study of the relationships among various 
definitions of high-risk prostate cancer and the pathologi-
cal characteristics of RP specimens and PSA relapse after 
RP found that, depending on its definition, 22-63% of pa-
tients had pathologically organ-confined disease, which is 
surgically curable with RP monotherapy or as part of a multi- 
modal approach [16]. The risk of PSA relapse clearly varies 
related to the definition used. From 41% to 74% of the pa-
tients remained progression-free at 10 years after RP. The 
10-year progression-free probability rate ranged from 41% 
(the lowest) in 1992 TNM clinical T3 and 74% (the highest) 
in the patients with high-risk cancer defined by a pre-
operative PSA velocity more than 2 ng/ml/year (Fig. 1).
NATURAL HISTORY OF HIGH-RISK PROSTATE 
CANCER
It is difficult to determine the natural history of high-risk 
prostate cancer. Because long-term survival rates are high 
in patients with prostate cancer, it is difficult to compare 
survival rates among risk groups. In addition, patients 
with high-risk prostate cancer are rarely allocated to active 
surveillance in contemporary cohorts. Several studies, 
however, can provide insights into the natural history of 
high-risk prostate cancer.
　In a prospective cohort study before the PSA era, Johansson 
et al described the natural history of initially untreated 
prostate cancer [17]. In the clinically localized group (clinical 
stage of T2 or less), the corrected 15-year overall survival 
rate was similar in patients with deferred treatment and 
in patients who received initial treatment (81% for both 
groups). Moreover, although prostate cancer accounted for 
37% of all deaths, only 11% of patients with localized di-
sease died due to prostate cancer. But the corrected 15-year 
overall survival was 57% in patients with locally advanced 
prostate cancer (clinical stage of T3-T4). Those authors con-
cluded that patients with locally advanced disease need tri-
als of aggressive therapy to improve their poor prognosis.
　Reviews of two population-based cohorts of men with lo-
calized prostate cancer in  the Connecticut Tumor Registry 
show the changes resulting from the introduction of wide-
spread PSA testing [18,19]. The first cohort consisted of pa-
tients  diagnosed with prostate cancer between 1971 and 
1984 before the advent of PSA testing, whereas the second 
cohort consisted of men diagnosed with prostate cancer be-
tween 1990 and 1992, at the start of widespread PSA 
testing.Korean J Urol 2010;51:589-595
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TABLE 1. Reported series of radical prostatectomy monotherapy for high-risk prostate cancer
No. of 
patients
Definition
Organ-
confined 
disease (%)
5-year 
BCR-free 
survival rate (%)
8-year 
BCR-free 
survival rate (%)
10-year 
BCR-free 
survival rate (%)
10-year 
CSS rate 
(%)
Gerber et al, 1997 [25] 298 cT3 9 29 57
Van den Ouden et al, 1998 [26] 83 cT3 18 29 72
Van Poppel et al, 2000 [27] 110 cT3 15 60 NA
D’Amico et al, 2002 [28] 429 D’Amico NA 33 NA
Freedland et al, 2007 [29] 56 cT3a 9 62 49 91
Loeb et al, 2009 [30] 175 D’Amico 36 68 92
BCR: biochemical recurrence, CSS: cancer-specific survival, NA: not assessed
　The first cohort consisted of 767 men with clinically lo-
calized prostate cancer who underwent watchful waiting 
alone [18]. The 15-year cancer-specific mortality rate in 
men with GS 6 was 18% to 30%, compared with a 25% to 
59% risk of death from other causes. The mortality rates 
from prostate cancer were higher in patients with GS 7 
(42% to 70%) and GS 8-10 (60% to 87%).
　In the second population-based cohort, the authors ex-
amined the survival of men 75 years or younger who had 
clinically localized prostate cancer, comparing those treated 
with RP, EBRT, or observation [19]. Patients were stratified 
according to several methods, to control for both known and 
unknown confounding factors. The cancer-specific mortal-
ity rates in high-risk patients by the D’Amico classification, 
were 2.3- and 3.4-fold higher in the RT and observation 
groups, respectively, than in the RP group. The estimated 
10-year cancer-specific survival rates in patients in the RP, 
EBRT, and observation groups were 90%, 80%, and 70%, 
respectively, for those with high-risk prostate cancer.
　These results suggest that patients with high-risk pro-
state cancer are at significant risk of disease progression 
and cancer-specific deaths if left untreated and that RP may 
provide a survival advantage over EBRT or observation.
RADIATION THERAPY WITH OR WITHOUT 
ANDROGEN DEPRIVATION THERAPY
The RT dose for the management of low-risk prostate can-
cer is recommended to be at least 72 Gy by the EAU guide-
lines [3], and ranges from 70 to 79 Gy according to the 2010 
NCCN guidelines [15]. The results of an M.D. Anderson 
Cancer Center trial showed that in patients with high-risk 
prostate cancer, dose escalation up to 78 Gy improves the 
results [20,21]. The 8-year biochemical recurrence-free rate 
was superior for the 78 Gy arm than for the 70 Gy arm (78% 
vs. 59%, p=0.004), and the benefit was even greater in pa-
tients with an initial PSA more than 10 ng/ml (78% vs. 39%, 
p=0.001). Moreover, the 8-year clinical failure rate was sig-
nificantly lower in the 78 Gy than in the 70 Gy arm (7% vs. 
15%, p=0.014), although the incidence of grade 2 or higher 
gastrointestinal toxicity was twice as high in the 78 Gy arm 
(26% vs. 13%) [21].
　Because EBRT is insufficient to cover the tumor beyond 
the pelvis, the benefit of adjuvant ADT was prospectively 
evaluated [22,23]. In a randomized, prospective trial of pa-
tients with locally advanced prostate cancer, the 5-year 
clinical disease-free survival rate was significantly higher 
in patients treated with 70 Gy EBRT plus 3 years of ADT 
than in those treated with 70 Gy EBRT alone (74% vs. 40%, 
p=0.0001), as were the 5-year overall survival rate (79% vs. 
62%, p=0.0002) and 5-year cancer-specific survival rate 
(94% vs. 79%, p=0.0001) [23].
　Based on these findings, the 2010 NCCN guidelines sug-
gest that RT doses between 78 and 80＋  Gy improve PSA- 
assessed disease control in patients with intermediate- or 
high-risk [15]. Moreover, these guidelines recommend pa-
tients with high-risk disease as candidates for pelvic lymph 
node irradiation and neoadjuvant/concomitant/adjuvant 
ADT for 2 to 3 years.
RADICAL PROSTATECTOMY MONOTHERAPY
There are two primary goals of treatment for patients with 
high-risk prostate cancer. The first is long-term cure, de-
fined as undetectable PSA or biochemical recurrence-free 
survival; although, due to the slow progression of prostate 
cancer, alternate definitions of cure are encompassed in 
metastasis-free survival and cancer-specific survival. The 
second goal is local disease control. Locally progressive 
prostate cancer can cause recurrent hematuria, urinary re-
tention, pain, and hydronephrosis, the relief of which re-
quires palliative surgical intervention.
　RP has been regarded as technically difficult in patients 
with high-risk prostate cancer and associated with high in-
cidences of side effects, including frequent incontinence. A 
prospective study, however, found that the recovery and 
continence rates following RP were similar in patients with 
locally advanced and low-risk prostate cancer [24]. Table 
1 summarizes the oncologic outcome in patients with high- 
risk prostate cancer treated with RP monotherapy.
　A pooled analysis of 298 patients with clinical T3 disease, 
only 27 (9%) with organ-confined disease, treated with RP 
monotherapy at several institutions in the United States 
and Europe found that the 5-year biochemical recurrence- 
free survival rates were 16% to 29% for patients with low- 
grade tumors versus 11% for patients with high-grade tu-Korean J Urol 2010;51:589-595
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mors (GS 8-10) [25]. The 10-year cancer-specific and meta-
stasis-free survival rates for all patients were 57% and 
32%, respectively, indicating that RP alone was unlikely 
to provide long-term survival benefits in men with high 
grade disease.
　RP monotherapy in 83 patients with clinical T3 prostate 
cancer, 15 (18%) with pathologically determined organ con-
fined disease, found that the 5-year rate of PSA progression 
was 71% and the 5- and 10-year cancer-specific survival 
rates were 85% and 72%, respectively [26]. These findings 
indicated that GS was a powerful predictor of recurrence 
and survival in patients with high PSA concentrations at 
diagnosis and failure to reach undetectable postoperative 
PSA.
　A study of 110 men with clinical stage T3 prostate cancer 
found that 15% of these patients actually had organ-confined 
disease, illustrating a small but significant overstaging 
that can occur in clinical T3 patients [27]. Following RP 
monotherapy, the 5-year biochemical recurrence-free sur-
vival rate was 40% and was strongly influenced by clinical 
stage and preoperative PSA.
　In a large, retrospective study including 2,635 patients 
treated with RP or RT in the PSA era, the initial rates of 
biochemical (PSA-free) survival in high-risk patients ini-
tially favored RT; however, the rates in the RP and RT groups 
were similar after 8 years (33% vs. 40%, respectively) [28].
　An assessment of long-term outcomes of RP in 56 patients 
with clinical T3a disease, 91% with pathological T3 disease, 
found that the 15-year biochemical recurrence-free, meta-
stasis-free, and cause-specific survival rates were 49%, 
73%, and 84%, respectively [29]. Among the 28 patients 
with PSA recurrence, a PSA doubling time ＜9 months was 
significantly associated with increased risk of prostate 
cancer deaths. These findings indicated that RP alone pro-
vided long-term cancer control in about half of these men 
and that the PSA doubling time at the time of recurrence 
is a useful determinant of risk of prostate cancer deaths 
among patients with PSA recurrence.
　A study of outcomes in 175 high-risk patients treated main-
ly with RP monotherapy found that, at a median follow-up 
of 8 years, 29% experienced biochemical progression, 3.4% 
had local recurrence, 13% developed metastatic disease, 
and 6% died due to prostate cancer [30]. The 10-year bio-
chemical recurrence-free, metastasis-free, and cancer-spe-
cific survival rates were 68%, 84%, and 92%, respectively.
　Taken together, the results of all of these studies show 
that 49-68% of patients with locally advanced prostate can-
cer were shown to achieve prolonged disease-free survival 
with RP alone [29,30]. More refined risk assessments are 
needed to determine whether surgical intervention alone 
or in combination with other therapies is optimal in in-
dividual patients with locally advanced prostate cancer.
MULTI-MODALITY THERAPY INCLUDING 
RADICAL PROSTATECTOMY
Regardless of the definition of high-risk prostate cancer, a 
substantial proportion of these patients require a multi- 
modality treatment approach that includes both local and 
systemic therapies. In recent years, several series of such 
multiple treatment approaches have been published, and 
RP has been shown to provide an excellent foundation for 
oncologic control of these patients. The 2010 NCCN guide-
lines recommend RP with pelvic lymph node dissection for 
selected patients with high-risk or very-high-risk prostate 
cancer without fixation to adjacent organs [15].
1. Neoadjuvant hormone therapy
The vast majority of patients will respond to initial hormo-
nal therapy, showing a significant shrinkage in the extent 
of the palpable tumor and a drop in serum PSA concentration. 
For example, the SWOG 9109 trial reported 5-year out-
comes in 55 patients with clinical T3-T4 prostate cancer 
treated with 4 months of neoadjuvant hormone therapy fol-
lowed by RP [31]. Nearly all patients showed significant 
shrinkage of the palpable tumor, and PSA was undetectable 
in 55%. RP was feasible in all 55 patients, with acceptable 
complications, with rectal injury occurring in only 1 patient. 
Approximately 80% of these patients became completely 
continent with no pads. Histological examination of the RP 
specimens revealed positive nodes in 19%, seminal vesicle 
invasion in 30%, and positive surgical margins in 30%. 
Despite this worrisome pathology, PSA remained undetec-
table in 70% of these patients after 5 years.
　Neoadjuvant hormonal therapy prior to RP was found to 
significantly reduce the proportion of patients with pos-
itive surgical margins (odds ratio [OR]: 0.34, 95% con-
fidence interval [CI]: 0.27-0.42, p＜0.00001) and to im-
prove other pathological variables such as lymph node in-
volvement, pathological staging, and organ-confined rates. 
In addition, there was a borderline significant reduction in 
disease recurrence rate (OR: 0.74, 95% CI: 0.55-1.0, p=0.05) 
[32]. Neoadjuvant hormonal therapy, however, did not sig-
nificantly increase overall and progression-free survival 
rates.
　Despite the lack of absolute evidence of efficacy, many 
urologists use neoadjuvant hormonal therapy in patients 
with clinical T3 disease for two reasons. First, it may make 
a potentially difficult surgery technically easier, perhaps 
improving the likelihood of obtaining negative surgical 
margins. Second, it cannot hurt and may even enhance a 
patient’s chance of long-term cure [33]. Nevertheless, neo-
adjuvant ADT for RP is strongly discouraged in the 2010 
NCCN guidelines [15].
2. Adjuvant radiation therapy
Although it seems logical that RT should improve cure 
rates after RP for patients with adverse pathological fea-
tures, nonrandomized studies showed no survival advant-
age despite improved local control [34]. Analysis of the effi-
cacy of adjuvant RT in patients with undetectable PSA and 
salvage RT in patients with increasing PSA has shown that 
biochemical recurrence-free survival rate is maximal in pa-
tients with undetectable PSA after RP [35,36]. These find-Korean J Urol 2010;51:589-595
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ings highlight the importance of the early application of 
combined modality treatment, when the tumor burden is 
at its lowest value and the likelihood of multiple sites of 
metastases is reduced.
　Two prospective, randomized controlled trials (EORTC 
22911 and SWOG 8794) have assessed the effectiveness of 
adjuvant RT. In the EORTC 22911 trial, 1,005 patients 
with a positive surgical margin or pT3 disease were ran-
domly assigned to adjuvant EBRT (60-65 Gy) or no ad-
juvant EBRT [37]. The 5-year biochemical progression- 
free survival (74% vs. 53%) and clinical progression-free 
survival (85% vs. 8%) were higher in patients receiving ad-
juvant EBRT, but there were no significant differences in 
5-year metastasis-free survival, cancer-specific survival, 
and overall survival rates. In the SWOG 8,794 trial, 425 pa-
tients with high-risk localized prostate cancer were ran-
domly assigned to adjuvant EBRT (60-65 Gy) or observation 
only [38]. The median PSA relapse-free survival (13.8 vs. 
10.3 years) and recurrence-free survival (9.9 vs. 3.1 years) 
periods were greater in the EBRT group. At a median fol-
low-up of 10.6 years, the cancer-specific mortality and over-
all survival rates were significantly greater in the adjuvant 
EBRT arm. The results of these two trials suggest that ad-
juvant EBRT immediately after RP improved biochemical 
recurrence-free survival and local control in patients with 
pathologically advanced prostate cancer who are at high 
risk of progression. However, the ability of adjuvant EBRT 
to enhance metastasis-free survival and overall survival is 
unclear.
3. Salvage radiotherapy
A large retrospective study of 501 patients treated with sal-
vage RT showed that the 4-year progression-free rate was 
45% [39]. Factors associated with poor response included 
preradiotherapy PSA more than 2 ng/ml, GS 8 to 10, PSA 
doubling time less than 10 months, negative tumor mar-
gins, and seminal vesicle invasion. Salvage EBRT can pro-
duce good responses in patients with preradiotherapy PSA 
is less than 1.0 ng/ml, or it may be better to start salvage 
RT as soon as biochemical recurrence is indicated.
4. Adjuvant hormone therapy
The use of hormonal therapy in high-risk patients after RP 
set the stage for such investigations. A retrospective analy-
sis of patients with regional lymph node-positive disease 
found that survival rates were improved in patients who 
underwent orchiectomy plus RP compared with those who 
underwent RP alone [40], although a second study showed 
contradictory results [41]. These findings indicated the 
need for prospective trials of hormonal therapy after RP in 
high-risk patients. In one trial, 100 patients were randomly 
assigned to receive either immediate hormone therapy or 
observation [42]. In 98 evaluable patients, assessed at a me-
dian follow-up of 7.1 years, early hormone therapy showed 
highly significant advantages, as shown by significantly 
increased cancer-specific, progression-free, and overall sur-
vival rates. Nevertheless, the inability of the study to reach 
its accrual goals and a lower than expected survival rate 
in the observation arm have raised concerns regarding whe-
ther hormone therapy should be a standard of care [43,44].
　The apparent survival advantage observed in patients 
treated with early and long-duration hormone therapy is 
reminiscent of the survival advantages observed in patients 
treated with EBRT plus hormone therapy [45]. Patients 
with lymph node-positive disease are best managed with 
adjuvant hormonal therapy. Messing et al demonstrated 
an improvement in biochemical recurrence-free survival 
(hazard ratio [HR]: 3.42, 95% CI: 1.96-5.98), cancer-specific 
survival (HR: 4.09, 95% CI: 1.76-9.49), and overall survival 
(HR: 1.84, 95% CI: 1.01-3.35) with immediate hormonal 
therapy after RP compared with therapy at the time of meta-
stasis [46]. Early adjuvant therapy based on improved risk 
assessments, both in patients with positive margins and 
those with positive lymph nodes, has been found to improve 
cure rates in patients in greatest need of cure.
5. Multi-modality therapy: radical prostatectomy, radi-
ation therapy, hormonal therapy, and chemotherapy
Although EBRT with ADT for 2 to 3 years is recommended 
for patients with high-risk prostate cancer in the 2010 NCCN 
guidelines, the optimal treatment for these patients has not 
yet been defined. We need more refined randomized studies 
of RP with neoadjuvant or adjuvant ADT and/or RT. We are 
also lacking information on chemotherapy in the neo-
adjuvant or adjuvant setting. RP, however, seems to be one 
of the most important modes of treatment in multi-modal 
therapy, maximizing survival in patients with locally ad-
vanced prostate cancer.
CONCLUSIONS
We believe in the value of aggressive surgical therapy for 
men with high-risk prostate cancer for the following 
reasons. Compared with observation alone, RP mono-
therapy may provide a long-term cancer-specific survival 
advantage, similar to that of EBRT. RP is the only method 
currently available for accurate pathological staging, re-
sulting in more accurate risk stratification and guiding the 
use of multi-modality therapy. Even in patients who fail 
surgery, RP allows the achievement of durable local 
control. More accurate stratification of the individual pa-
tient’s risk for progression and likelihood of response to 
treatment is required. In addition, it is necessary to in-
dividualize the timing and type of adjuvant therapy.
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